PROGRAM

SUNDAY, October 22—7:00 PM

Welcome Remarks

KEYNOTE SPEAKER

Introduction by: Xuetao Cao, Chinese Academy of Medical Sciences, Shanghai, China

Personalizing cancer immunotherapy
Robert D. Schreiber
Presenter affiliation: Washington University School of Medicine, St Louis, Missouri.

MONDAY, October 23—9:00 AM

SESSION 1 IMMUNE REGULATION IN THE TUMOR MICROENVIRONMENT I

Chairperson: Dmitry Gabrilovich, The Wistar Institute, Philadelphia, Pennsylvania, USA

Myeloid-derived suppressor cells—Biology and therapeutic regulation
Dmitry Gabrilovich
Presenter affiliation: The Wistar Institute, Philadelphia, Pennsylvania; Sun Yat-Sen University, Guangzhou, China.

Epigenetic modifiers in the innate inflammation and cancer
Xuetao Cao
Presenter affiliation: Chinese Academy of Medical Sciences, Beijing, China; Second Military Medical University, Shanghai, China.

Break
CD137 ligand signaling induces differentiation of human monocytes to inflammatory dendritic cells which potently drive cellular immune responses
Herbert Schwarz, Bhushan Dharmadhikari, Zulkarnain Harfuddin, Emily Nickles, Antonio Bertoletti  [15'+5']
Presenter affiliation: National University of Singapore, Singapore.  

Tumor microenvironment supports the self-maintenance of intestinal tissue-resident macrophages
Irene Soncin, Jianpeng Sheng, Qi Chen, Klaus Karjalainen, Christiane Ruedl  [15'+5']
Presenter affiliation: Nanyang Technological University, Singapore.  

Blocking lipid metabolism in the tumor microenvironment promotes the development of effective anti-tumor responses
Augusto C. Ochoa  [25'+10']
Presenter affiliation: Louisiana State University, New Orleans, Louisiana.  

MONDAY, October 23—2:00 PM

SESSION 2 POSTER SESSION

Manufacture of T4 immunotherapy—An autologous panErbB-targeted CAR T-cell product under Phase I evaluation in head and neck squamous cell carcinoma
Antonella Adami, Michael Metoudi, Sophie Papa, Daniela Achkova, Jean Pierre Jeannon, John Maher
Presenter affiliation: King's College London-Guy's Hospital, London, United Kingdom.  

Tracking L-selectin enhanced T cells in cancer immunotherapy using micro-PET/CT
Ann Ager, Angharad Watson, Julia Ohme, Markella Alatsatianos, Stephen Paisey, Christopher Marshall
Presenter affiliation: Cardiff University School of Medicine, Cardiff, United Kingdom.  

An antagonistic role of the inducible proteasome subunits in MHC class I presentation of canonical and spliced tumour epitopes
Nadine Andresen, Richard Golnik, Andrea Lehmann, Michele Mishto, Peter-Michael Kloeetz, Frédéric Ebstein
Presenter affiliation: Charité-Universitätsmedizin Berlin, Berlin, Germany.

Empowering liver cancer immunotherapy by specific inhibition of histone deacetylase 8
Alfred Sze Lok Cheng, Weiqin Yang, Yu Feng, Jingying Zhou, Hangyong Sun, Zhiwei Chen
Presenter affiliation: The Chinese University of Hong Kong, Hong Kong.

Selective HDAC6 inhibitors with immunomodulatory properties, has significant anti-melanoma activity in vitro and in vivo
Fengdong Cheng, Jie Chen, Andressa Sodre Laino, Alejandro Villagra, Jeffrey Weber, Quayle Steven, Simon Jones, Eduardo M. Sotomayor
Presenter affiliation: GW Cancer Center, George Washington University, Washington, DC

Leukotrienes mediated neutrophils-promoted xenograft formation
Ka-Long Chu, Chun Chu, Susanna S. Lee, Helen Wise, Wing-Tai Cheung
Presenter affiliation: The Chinese University of Hong Kong, Hong Kong.

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
CS Chim
Presenter affiliation: University of Hong Kong, Hong Kong, China.

STING agonist modulates tumor immune microenvironment of non-inflamed lung cancer to potentiate the efficacy of immune checkpoint blockade
Hongjae Chon, Chan Kim
Presenter affiliation: CHA University, Seongnam, South Korea; CHA Bundang Medical Center, Seongnam, South Korea.
Immune cell profiling in the tumor microenvironment for triple negative breast cancer
Hye Hyeon Eum, You-rae Hong, Nayoung Kim, Areum Jo, Woosung Chung, JaeYong Nam, Han-Byoel Lee, WonShik Han, Woong-Yang Park, Hae-Ock Lee
Presenter affiliation: Samsung Medical Center, Seoul, South Korea; Seoul National University Graduate School, Seoul, South Korea.

Inhibition of p21 activated kinase 1 enhances tumour immune response and suppresses tumour growth
Hong He, Nhi Huynh, Kai Wang, Mildred Yim, Chelsea J. Dumesny, Mauro S. Sandrin, Graham S. Baldwin, Mehrdad Nikfarjam
Presenter affiliation: University of Melbourne, Melbourne, Australia.

Formulation and delivery of a dual COX-2/5-LO inhibitor in combination with a therapeutic cancer vaccine
Blake Gibson, David Larsen, Sarah Hook
Presenter affiliation: University of Otago, Dunedin, New Zealand.

A novel oncolytic virus expressing multiple immune regulatory factors to change tumor immune microenvironment and to cause lasting complete tumor eradication in animal models
Presenter affiliation: University of British Columbia, Vancouver, Canada; Virogin Biotech, Vancouver, Canada.

A novel high-throughput method for quantification of microbiota distribution at the single cell level
Jianshi Jin, Tadashi Takeuchi, Eiji Miyauchi, Hiroshi Ohno, Katsuyuki Shiroguchi
Presenter affiliation: RIKEN, Osaka, Japan.

Dendritic cell-based vaccine treated with polysorbitol transporter enhanced antigen-specific CD8+ T cell immune response through cross-presentation
Cheol Gyun Kim, Narae Kim, Min Jeong Gu, Yoon Chul Kye, Seung Hyun Han, Cheol-Heui Yun
Presenter affiliation: Seoul National University, Seoul, South Korea.

Ten lessons learned from big data immunology and relevance to cancers
Shuzhao Li
Presenter affiliation: Emory University, Atlanta, Georgia.
Dissecting the immunological mechanisms underlying the efficacy of neoadjuvant immunotherapy
Jing Liu, Jake s. O'Donnell, Stacey Allen, Mark J. Smyth, Michele Teng
 Presenter affiliation: QIMR Berghofer Medical Research Institute, Brisbane, Australia; University of Queensland School of Medicine, Brisbane, Australia.

Phase I Clinical Trial Report—T4 immunotherapy of head and neck squamous cell carcinoma (HNSCC) using Pan-ErbB targeted CAR T-cells
 Presenter affiliation: King's College London, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Eastbourne Hospital, Eastbourne, United Kingdom.

Comparative analysis of immune molecules in esophageal squamous cell carcinoma and adenocarcinoma
Guohui Qin, Jingyao Lian, Ling Cao, Shasha Liu, Yujia Zheng, Lan Huang, Yi Zhang
 Presenter affiliation: the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Personal regulome dynamics of cutaneous T cell lymphoma
Kun Qu, Lisa C. Zaba, Yonghao Jin, Chen Jin, Youn H. Kim, Howard Y. Chang
 Presenter affiliation: University of Science and Technology of China, Hefei, China; Stanford University School of Medicine, Stanford, California.

LRBA deficiency may incur an increased risk for gastric cancer
Erez Rechavi, Atar Lev, Amos J. Simon, Hana Golan, Ortal Barel, Amos Toren, Raz Somech
 Presenter affiliation: Tel Aviv University, Tel Aviv, Israel; Sheba Medical Center, Ramat Gan, Israel.

Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
Jin Hai Zheng, Wenzhi Tan, Hyon E. Choy, Shee Eun Lee, Jung-Joon Min, Joon Haeng Rhee
 Presenter affiliation: Chonnam National University Medical School, Hwasun, South Korea.
Human anti-citrullinated fibrinogen antibody (AhFibA) in rheumatoid arthritis
Reza Saghiri, Shohreh Khatami, Mina Ebrahimi-Rad
Presenter Affiliation: Institute Pasteur of Iran, Tehran, Iran.

PD-L1 on host cells is essential for tumor regression mediated by PD-L1 blockade
Haidong Tang, Yong Liang, Xiangyan Qiu, Aditi Mulgaonkar, Haidong Dong, Yang-Xin Fu
Presenter affiliation: UT Southwestern Medical Center, Dallas, Texas.

Low dose radiation induced anti-tumor immunity
Michelle Bugden, Yi Wang
Presenter affiliation: Canadian Nuclear Laboratories, Chalk River, Canada.

Andrographolide derivative for the treatment of inflammatory bowel disease and associated cancer
Ying Wang
Presenter affiliation: University of Macau, Macao, China.

Blocking IL-23R compared to neutralizing IL-23p19 is more effective in suppressing experimental lung metastases
Juming Yan, Stacey Allen, Dipti Vijayan, Kazuyoshi Takeda, Daniel Cua, Mark Smyth, Michele Teng
Presenter affiliation: QIMR Berghofer Medical Research Institute, Brisbane, Australia; University of Queensland School of Medicine, Brisbane, Australia.

A β-glucan from Durvillaea antarctica exerts immunomodulatory effects on RAW264.7 macrophages via Toll-like receptor 4
Yi Yang, Xiao L. Zhao, Hao Jiang, Xin D. Shan, Ya Wang, Guang L. Yu
Presenter affiliation: Ocean University of China, Qingdao, China.

The characteristics of TNFR2+Tregs in gastric cancer tissues and the relationship with clinical data and outcomes
Yuan Yao, Hui Li
Presenter affiliation: Tianjin Medical University Cancer Institute, Tianjin, China.
Insights into cytokine-mediated triple-negative breast cancer progression from genome-wide profiling of transcription factor AP-1  
Yichun Qiao, Chunyan Zhao  
Presenter affiliation: Karolinska Institutet, Stockholm, Sweden.  

The short-term outcome of postoperative 131I-labeled Metuximab (Licartin) adjuvant therapy for hepatocellular carcinoma with high recurrence risk  
Gang Zhao, Hui Li  
Presenter affiliation: Tianjin Medical University Cancer Institute, Tianjin, China.  

Inhibition of hepatoma-intrinsic CCRK enhances the efficacy of anti-PD-L1 blockade therapy by altering tumor suppressive microenvironment in HCC  
Jingying Zhou, Alfred Sze Lok Cheng  
Presenter affiliation: The Chinese University of Hong Kong, Hong Kong, Hong Kong.  

MONDAY, October 23—4:30 PM  
Chinese Tea and Beer Tasting  

MONDAY, October 23—7:00 PM  

SESSION 3  IMMUNE REGULATION IN THE TUMOR MICROENVIRONMENT II  

Chairperson: Zhigang Tian, University of Science and Technology of China, Hefei, China  

TIGIT blockade prevents NK cell exhaustion and elicits potent anti-tumor immunity  
Zhigang Tian  [25'+10']  
Presenter affiliation: University of Science & Technology of China, Hefei, China.
Harnessing natural killer receptors against cancer
Adelheid Cerwenka [25'+10']
Presenter affiliation: German Cancer Research Center, Heidelberg, Germany.

Break

A dual-targeting nanocarrier suppresses melanoma growth through blockade of CSF1R signaling in tumor-associated macrophage
Yuan Qian, Sha Qiao, Zhihong Zhang [15'+5']
Presenter affiliation: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, China; MoE Key Laboratory for Biomedical Photonics, Wuhan, China. 39

Tumor-associated macrophages produce interleukin-10 to promote cancer stem cell-like properties in human non-small cell lung cancer
Li Yang, Yi Zhang [15'+5']
Presenter affiliation: the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 40

The rise of immuno-epitranscriptomics
Gideon Rechavi [25'+10']
Presenter affiliation: Sheba Medical Center, Tel Hashomer, Israel; Tel Aviv University, Tel Aviv, Israel. 41

TUESDAY, October 24—9:00 AM

SESSION 4 MECHANISMS OF IMMUNE SUPPRESSION IN CANCER I

Chairperson: E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Molecular basis of T cell exhaustion—Insights for immunotherapy
E John Wherry [25'+10']
Presenter affiliation: University of Pennsylvania, Philadelphia, Pennsylvania. 42
Inhibitory mechanisms in cancer
Dario Vagnali  [25'+10']
Presenter affiliation: University of Pittsburgh, Pittsburgh, Pennsylvania.

Break

Potentiating the antitumour response of CD8\(^+\) T cells by modulating cholesterol metabolism
Wei Yang, Yibing Bai, Bo-liang Li, Chenqi Xu  [15'+5']
Presenter affiliation: Institute of Biochemistry and Cell Biology, Shanghai, China.

Activation of CD137L-DC is dependent on Akt-driven glycolysis
Qun Zeng, Herbert Schwarz  [15'+5']
Presenter affiliation: National University of Singapore, Yong Loo Lin School of Medicine, Singapore.

Regulating anti-tumor immunity
Pamela S. Ohashi  [25'+10']
Presenter affiliation: Princess Margaret Cancer Centre, Toronto, Canada.

TUESDAY, October 24—2:00 PM

SESSION 5  MECHANISMS OF IMMUNE SUPPRESSION IN CANCER II

Chairperson: Suzanne Ostrand-Rosenberg, University of Maryland Baltimore County, Baltimore, Maryland, USA

Myeloid-derived suppressor cells (MDSC)—Their ying and yang effects in tumor-bearing obese mice
Suzanne Ostrand-Rosenberg  [25'+10']
Presenter affiliation: University of Maryland Baltimore County, Baltimore, Maryland.

Metabolic control of immune cell subsets in the tumor microenvironment
Weiping Zou  [25'+10']
Presenter affiliation: University of Michigan, Ann Arbor, Michigan.
Deletion of tumor complement C3 enables anti PD-L1 antibody efficacy
Haoran Zha, Ying Zhu, Xiao Han, Fei Yang, Chunyan Hu, Chi Shu, Yi Feng, Yongsheng Li, Jinyu Zhang, Yongsheng Li, Bo Guo, Bo Zhu [15'+5']
Presenter affiliation: Xinqiao Hospital, Third Military Medical University, Chongqing, China; Chongqing Key Laboratory of Immunotherapy, Chongqing, China.

Regulation of the central innate immunity mediator MyD88 and its role in cancer
Monika Avbelj, Mateja Mancek Keber, Iva Hafner Bratkovic, Dusko Lainscek, Roman Jerala [15'+5']
Presenter affiliation: National Institute of Chemistry, Ljubljana, Slovenia.

Break

Targeting tumor cells to trigger immunity
Yang-Xin Fu [25'+10']
Presenter affiliation: UT Southwestern Medical Center, Dallas, Texas.

Enhancing adoptive cellular therapy by targeting tumor-induced immunosuppression
Phillip K. Darcy [25'+10']
Presenter affiliation: Peter MacCallum Cancer Centre, Melbourne, Australia.

Hepatic ISGs expression predicts interferon-α therapeutic response in hepatocellular carcinoma patients
Jin Hou [15'+5']
Presenter affiliation: Second Military Medical University, Shanghai, China.

Introduction on innovative single cell genomics technologies from 10X Genomics
Yafei Liu [15'+5']
Presenter affiliation: 10X Genomics, Beijing, China.

TUESDAY, October 24—After Dinner

Free open bar
SESSION 6 TUMOR ANTIGEN-SPECIFIC IMMUNOTHERAPY

Chairperson: Pramod Srivastava, University of Connecticut School of Medicine, Farmington, Connecticut, USA

Predicting good cancer neoepitopes—The consensus and the evidence
Pramod K. Srivastava [25'+10']
Presenter affiliation: University of Connecticut School of Medicine, Farmington, Connecticut. 54

Augmenting and broadening T-cell responses against mutated tumor neo-antigens
Bruce W. Robinson [25'+10']
Presenter affiliation: University of Western Australia, Perth, Western Australia, Australia. 55

Cancer vaccines and immunotherapy—Translation from mice to human clinical trials
Jay A. Berzofsky [25'+10']
Presenter affiliation: National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 56

Break

Shared tumor antigens as prophylactic vaccines and immunotherapy targets
Olivera J. Finn [25'+10']
Presenter affiliation: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 57

IdealImmune—A better mouse model for evaluation of cancer immunotherapy
Song Chang, Xinmiao Zhang, Yirong Kong, Jinxia Shi, Siying Peng [15'+5']
Presenter affiliation: Beijing IDMO Co., Ltd., Beijing, China. 58

Next generation chimeric antigen receptor (CAR) T cells
Renier J. Brentjens [25'+10']
Presenter affiliation: Memorial Sloan Kettering Cancer Center, New York, New York. 59
WEDNESDAY, October 25—1:30 PM

Visit to Old Suzhou

WEDNESDAY, October 25—6:00 PM

COCKTAILS and BANQUET

THURSDAY, October 26—9:00 AM

KEYNOTE SPEAKER

Introduction by: Olivera Finn, University of Pittsburgh, USA

Intestinal microbiome as a new partner in immuno-oncology
Laurence Zitvogel  50’+10’
Presenter affiliation: Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, France; University of Paris Sud, Paris, France.

THURSDAY, October 26—10:00 AM

SESSION 7  OTHER APPROACHES TO IMMUNOTHERAPY

Chairperson: Alberto Mantovani, Humanitas Clinical and Research Center, Milan, Italy

The yin-yang of innate immunity, inflammation and cancer
Alberto Mantovani  25’+10’
Presenter affiliation: Humanitas Clinical and Research Center; Humanitas University, Rozzano, Milan, Italy.

Immune-mediated effects of cytotoxic and targeted anticancer agents
Guido Kroemer  25’+10’
Presenter affiliation: University of Paris Descartes, Paris, France; INSERM U1138, Paris, France; Hopital Européen George Pompidou, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France.